BioWorld-International-2005-11-16
IDM Initiating Third Phase II Trial Of Uvidem In Melanoma
IDM Initiating Third Phase II Trial Of Uvidem In Melanoma
PARIS - IDM Pharma Inc. initiated another Phase II trial of its therapeutic vaccine Uvidem, which it is developing in collaboration with Sanofi-Aventis for the treatment of melanoma. (BioWorld International)

